Literature DB >> 7846013

Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.

R E Ritts1, D M Nagorney, D J Jacobsen, R W Talbot, V R Zurawski.   

Abstract

A prospective, blinded study of CA19-9 in 2,467 patients having abdominal surgery yielded 356 patients with pancreatic, gallbladder, and biliary disease who submitted coded preoperative serum specimens. In this group, there were 84 patients with pancreatic cancer and 24 patients with gallbladder-biliary cancer; the remainder had benign lesions. The recorded imaging data and marker results were merged with the patients' demographic, clinical, and surgical data and tissue diagnoses for analysis. Receiver operator character calculation suggested that a reference value of 100 U/ml for CA19-9 was appropriate rather than the 37-40 U/ml value most frequently employed and yielded a specificity of 97% in the 467 operated patients with a sensitivity of 8.3% for all nonpancreatic-biliary cancers and 62% overall for these lesions. In the more diagnostically challenging nonicteric patients, CA19-9 sensitivity was 55%, specificity was > 99%, positive predictive value (PPV) was 97%, and negative predictive value (NPV) was 88%. When CA19-9 results were combined with those from endoscopic retrograde cholangiopancreatography, ultrasound (US), or computed tomography (CT), the PPV, and especially the NPV were increased. The addition of carcinoembryonic antigen results did not affect overall results. The addition of CA19-9 results to ambiguous or indeterminant imaging interpretation clearly improved the combined specificity, sensitivity, and PPV, but the change was less impressive, albeit positive, for NPV. The combination of CA19-9 and CT (or US) is a reasonable, cost-effective, noninvasive approach to establishing the diagnosis of pancreatic, cholangitic, or biliary cancer in nonicteric patients. Although no single procedure or combination of procedures was found to detect early, small lesions, CA19-9 is clearly a clinically useful adjunct to imaging in nonjaundiced patients suspected of having these malignancies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846013     DOI: 10.1097/00006676-199411000-00006

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  14 in total

1.  Implications of the index cholecystectomy and timing of referral for radical resection of advanced incidental gallbladder cancer.

Authors:  T Tsirlis; F Ausania; S A White; J J French; B C Jaques; R M Charnley; D M Manas
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

2.  Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.

Authors:  Tingting Yue; Katie Partyka; Kevin A Maupin; Mary Hurley; Philip Andrews; Karen Kaul; A James Moser; Herbert Zeh; Randall E Brand; Brian B Haab
Journal:  Proteomics       Date:  2011-08-02       Impact factor: 3.984

3.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

4.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

5.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

6.  Gallbladder Carcinoma, the Difficulty of Early Detection: A Case Report.

Authors:  Andrew E Graff; Stephen L Lewis; Jonathan R Bear; David C Van Echo; Hugh M Dainer
Journal:  Cureus       Date:  2016-02-12

Review 7.  Pancreatic cancer: can we screen? How should we stage?

Authors:  A A Parikh; A M Lowy
Journal:  Curr Gastroenterol Rep       Date:  1999-04

8.  Implication of suspicious cytology in endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer.

Authors:  Jiaqi Shi; Madelyn Lew; Mark M Zalupski; Michael H Roh; Richard S Kwon; Judy C Pang
Journal:  J Gastrointest Cancer       Date:  2015-03

Review 9.  Pancreatic cancer.

Authors:  S J Cohen; W H Pinover; J C Watson; N J Meropol
Journal:  Curr Treat Options Oncol       Date:  2000-12

Review 10.  Surgical treatment of gallbladder carcinoma: a critical review.

Authors:  Farzad Kakaei; Samad Beheshtirouy; Seyed Mohammadreza Nejatollahi; Sina Zarrintan; Mohammad Reza Mafi
Journal:  Updates Surg       Date:  2015-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.